Increased KL-6 levels in moderate to severe COVID-19 infection.

Autor: Cambier M; Department of Pneumology, University Hospital of Liège, Liège, Belgium.; Laboratory of Molecular Angiogenesis, GIGA Research Center, University of Liège, Liège, Belgium., Henket M; Department of Pneumology, University Hospital of Liège, Liège, Belgium., Frix AN; Department of Pneumology, University Hospital of Liège, Liège, Belgium., Gofflot S; Biothèque Hospitalo-Universitaire de Liège, University Hospital of Liège, Liège, Belgium., Thys M; Department of Biostatistics and Medico-Economic Information, University Hospital of Liège, Liège, Belgium., Tomasetti S; Department of Experimental and Clinical Medicine, Careggi University Hospital, Florence, Italy., Peired A; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy., Struman I; Laboratory of Molecular Angiogenesis, GIGA Research Center, University of Liège, Liège, Belgium., Rousseau AF; Department of Intensive Care, University Hospital of Liège, Liège, Belgium., Misset B; Department of Intensive Care, University Hospital of Liège, Liège, Belgium., Darcis G; Department of Infectious Diseases and General Internal Medicine, Liège University Hospital, Liège, Belgium., Moutschen M; Department of Infectious Diseases and General Internal Medicine, Liège University Hospital, Liège, Belgium.; AIDS Reference Laboratory, Liège University, Liège, Belgium., Louis R; Department of Pneumology, University Hospital of Liège, Liège, Belgium.; Fibropole Research Group, GIGA Research Center, University of Liège, University Hospital of Liège, Liège, Belgium., Njock MS; Department of Pneumology, University Hospital of Liège, Liège, Belgium.; Fibropole Research Group, GIGA Research Center, University of Liège, University Hospital of Liège, Liège, Belgium., Cavalier E; Department of Clinical Chemistry, University of Liège, University Hospital of Liège, Liège, Belgium., Guiot J; Department of Pneumology, University Hospital of Liège, Liège, Belgium.; Fibropole Research Group, GIGA Research Center, University of Liège, University Hospital of Liège, Liège, Belgium.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2022 Nov 28; Vol. 17 (11), pp. e0273107. Date of Electronic Publication: 2022 Nov 28 (Print Publication: 2022).
DOI: 10.1371/journal.pone.0273107
Abstrakt: Background: The global coronavirus disease 2019 (COVID-19) has presented significant challenges and created concerns worldwide. Besides, patients who have experienced a SARS-CoV-2 infection could present post-viral complications that can ultimately lead to pulmonary fibrosis. Serum levels of Krebs von den Lungen 6 (KL-6), high molecular weight human MUC1 mucin, are increased in the most patients with various interstitial lung damage. Since its production is raised during epithelial damages, KL-6 could be a helpful non-invasive marker to monitor COVID-19 infection and predict post-infection sequelae.
Methods: We retrospectively evaluated KL-6 levels of 222 COVID-19 infected patients and 70 healthy control. Serum KL-6, fibrinogen, lactate dehydrogenase (LDH), platelet-lymphocytes ratio (PLR) levels and other biological parameters were analyzed. This retrospective study also characterized the relationships between serum KL-6 levels and pulmonary function variables.
Results: Our results showed that serum KL-6 levels in COVID-19 patients were increased compared to healthy subjects (470 U/ml vs 254 U/ml, P <0.00001). ROC curve analysis enabled us to identify that KL-6 > 453.5 U/ml was associated with COVID-19 (AUC = 0.8415, P < 0.0001). KL-6 level was positively correlated with other indicators of disease severity such as fibrinogen level (r = 0.1475, P = 0.0287), LDH level (r = 0,31, P = 0,004) and PLR level (r = 0.23, P = 0.0005). However, KL-6 levels were not correlated with pulmonary function tests (r = 0.04, P = 0.69).
Conclusions: KL-6 expression was correlated with several disease severity indicators. However, the association between mortality and long-term follow-up outcomes needs further investigation. More extensive trials are required to prove that KL-6 could be a marker of disease severity in COVID-19 infection.
Competing Interests: JG reports personal fees for advisory board, work and lectures from Boehringer Ingelheim, Janssens, GSK, Roche and Chiesi, non-financial support for meeting attendance from Chiesi, Roche, Boehringer Ingelheim and Janssens. He is in the permanent SAB of Radiomics (Oncoradiomics SA) for the SALMON trial without any specific consultancy fee for this work. He is co-inventor of one issued patent on radiomics licensed to Radiomics (Oncoradiomics SA). He confirms that none of the above entities or funding was involved in the preparation of this work. There are no patents, products in development or marketed products associated with this research to declare.
(Copyright: © 2022 Cambier et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje